The enforcement scale is real: more than 455 FDA adverse-event reports tied to compounded semaglutide, over 50 warning letters to compounded GLP-1 sellers in 2025, and 30-plus more in March 2026, several of them naming the compounding pharmacies behind telehealth brands
This blog is an extension of our poster presented at ISPOR 2025, titled Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation
Through high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based molecular weight identification, standard molecular weight comparison, and characteristic HPLC profiles of the [ 3 H]proline and [ 3 H]BPC157 standards (Supplementary Figure S2), we speculated the structures of these six components and designated them as M1M6 (Table 10)
Curr Ther Res 1982;31:1042-1048
Used in combination (in separate injections), they: Promote faster recovery from injury or surgery Support joint, tendon, and ligament health Reduce systemic inflammation and pain Help regulate immune response and tissue regeneration Improve mobility, flexibility, and structural resilience BPC-157 helps protect and rebuild from the inside, while TB500 supports mobility, flexibility, and circulation